XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Organization (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
candidate
subsidiary
Dec. 31, 2021
USD ($)
Mar. 10, 2021
trial
subject
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Number of additional trials | trial     3
Number of clinical trial subjects | subject     1,000
Number of product candidates | candidate 4    
Number of subsidiaries | subsidiary 3    
Accumulated deficit $ 684,746 $ 674,547  
Cash, cash equivalents and marketable securities $ 79,038 $ 87,326